Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 619. The title of the hearing was ``Legislative
Proposals to Support Patients and Caregivers.'' The
Subcommittee received testimony from:
Andy Shih, Ph.D., Chief Science Officer,
Autism Speaks;
Corey Feist, J.D., M.B.A., Co-Founder and
CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, M.D., Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and
Christina Annunziata, M.D., Ph.D., Senior
Vice President of Extramural Discovery Science,
American Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 619, as amended, to the full
Committee by a record vote of 26 yeas and 0 nays.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 619, as
amended, favorably reported to the House by a record vote of 43
yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize the National Alzheimer's Project though 2035 and to
make certain modifications to the Project structure, including
the Project's purpose and the composition of the Advisory
Council on Alzheimer's Research, Care and Services by expanding
the membership and its reporting requirements.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 619 is known to be duplicative of another Federal program,
including any program that was included in a report to Congress
pursuant to section 21 of Public Law 111-139 or the most recent
Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 619:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 619. The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 619 contains no earmarks, limited tax
benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the ``NAPA
Reauthorization Act''.
Section 2. Extension of National Alzheimer's Project
Section 2 amends Section 2 of the National Alzheimer's
Project Act by extending the program through 2035, as well as
including preventative approaches within the purpose of the
project and making certain modifications to the Advisory
Council on Alzheimer's Research, Care, and Services.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
NATIONAL ALZHEIMER'S PROJECT ACT
* * * * * * *
SEC. 2. THE NATIONAL ALZHEIMER'S PROJECT.
(a) Definition of Alzheimer's.--In this Act, the term
``Alzheimer's'' means Alzheimer's disease and related
dementias.
(b) Establishment.--There is established in the Office of the
Secretary of Health and Human Services the National Alzheimer's
Project (referred to in this Act as the ``Project'').
(c) Purpose of the Project.--The Secretary of Health and
Human Services, or the Secretary's designee, shall--
(1) be responsible for the creation and maintenance
of an integrated national plan to overcome Alzheimer's;
(2) provide information [and coordination of] on, and
coordination of, Alzheimer's research and services
across all Federal agencies;
(3) accelerate the development of treatments that
would prevent, halt, or reverse the course of
Alzheimer's;
(4) improve the--
(A) promotion of healthy aging and reduction
and mitigation of risk factors for Alzheimer's;
[(A)] (B) early diagnosis of Alzheimer's
disease; and
[(B)] (C) coordination of the care and
treatment of citizens with Alzheimer's;
(5) ensure the inclusion of ethnic and racial
populations and other underserved populations,
including individuals with developmental disabilities
such as Down syndrome, at higher risk for Alzheimer's
or least likely to receive care, in clinical, research,
and service efforts with the purpose of decreasing
health disparities in Alzheimer's[; and];
(6) provide information on, and promote the adoption
of, healthy behaviors that may reduce the risk of
cognitive decline and promote and protect cognitive
health; and
[(6)] (7) coordinate with international bodies to
integrate and inform the fight against Alzheimer's
globally.
(d) Duties of the Secretary.--
(1) In general.--The Secretary of Health and Human
Services, or the Secretary's designee, shall--
(A) oversee the creation and updating of the
national plan described in paragraph (2); and
(B) use discretionary authority to evaluate
all Federal programs around Alzheimer's,
including budget requests and approvals.
(2) National plan.--The Secretary of Health and Human
Services, or the Secretary's designee, shall carry out
an annual assessment of the Nation's progress, across
public and private sectors, in preparing for the
escalating burden of Alzheimer's, including both
implementation steps and recommendations for priority
actions based on the assessment, including
consideration of public-private collaborations, as
appropriate.
(e) Advisory Council.--
(1) In general.--There is established an Advisory
Council on Alzheimer's Research, Care, and Services
(referred to in this Act as the ``Advisory Council'').
(2) Membership.--
(A) Federal members.--The Advisory Council
shall be comprised of the following experts:
(i) A designee of the Centers for
Disease Control and Prevention.
(ii) A designee of the Administration
on Aging.
(iii) A designee of the Centers for
Medicare & Medicaid Services.
(iv) A designee of the Indian Health
Service.
(v) A designee of the Office of the
Director of the National Institutes of
Health.
(vi) The Surgeon General.
(vii) A designee of the National
Science Foundation.
(viii) A designee of the Department
of Veterans Affairs.
(ix) A designee of the Food and Drug
Administration.
(x) A designee of the Agency for
Healthcare Research and Quality.
(xi) A designee of the Department of
Justice.
(xii) A designee of the Social
Security Administration.
(xiii) A designee of the Federal
Emergency Management Agency.
(xiv) 2 or more other designees of
the Department of Health and Human
Services, at least one of whom has
expertise in risk factors associated
with the development or the progression
of Alzheimer's disease, as determined
by the Secretary of Health and Human
Services.
(B) Non-federal members.--In addition to the
members outlined in subparagraph (A), the
Advisory Council shall include [12] 14 expert
members from outside the Federal Government,
which shall include--
(i) 2 Alzheimer's patient advocates;
(ii) 2 Alzheimer's caregivers;
(iii) 2 health care providers;
(iv) 2 representatives of State
health departments;
(v) [2 researchers] 3 researchers
with Alzheimer's-related expertise in
basic, translational, clinical, or drug
development science[; and], including
at least one researcher with
demonstrated experience in recruitment
and retention of underrepresented
groups into research or clinical trials
related to dementia;
(vi) 2 voluntary health association
representatives, including a national
Alzheimer's disease organization that
has demonstrated experience in
research, care, and patient services,
and a State-based advocacy organization
that provides services to families and
professionals, including information
and referral, support groups, care
consultation, education, and safety
services[.]; and
(vii) 1 individual with a diagnosis
of Alzheimer's disease.
(3) Meetings.--The Advisory Council shall meet
quarterly and such meetings shall be open to the
public.
(4) Advice.--The Advisory Council shall advise the
Secretary of Health and Human Services, or the
Secretary's designee.
(5) Annual Report.--The Advisory Council shall
provide to the Secretary of Health and Human Services,
or the Secretary's designee and Congress--
(A) [an initial evaluation] annual
evaluations of all federally funded efforts in
Alzheimer's [research, clinical] research, risk
reduction, public health, clinical care, and
institutional-, home-, and community-based
programs and their outcomes;
(B) [initial] annual recommendations for
priority actions to expand, eliminate,
coordinate, or condense programs based on the
program's performance, mission, and purpose;
(C) [initial] annual recommendations to--
(i) reduce the financial impact of
Alzheimer's on--
(I) Medicare and other
federally funded programs; and
(II) families living with
Alzheimer's disease; and
(ii) improve health outcomes and
reduce disparities; and
(D) [annually thereafter, an evaluation]
annual evaluations of the implementation,
including outcomes, of the recommendations,
including priorities if necessary, through an
updated national plan under subsection (d)(2).
(6) Termination.--The Advisory Council shall
terminate on December 31, [2025] 2035.
(f) Data Sharing.--Agencies both within the Department of
Health and Human Services and outside of the Department that
have data relating to Alzheimer's shall share such data with
the Secretary of Health and Human Services, or the Secretary's
designee, to enable the Secretary, or the Secretary's designee,
to complete the report described in subsection (g).
(g) Annual report.--The Secretary of Health and Human
Services, or the Secretary's designee, shall submit to
Congress--
(1) an annual report [that includes an evaluation]
that includes--
(A) an evaluation of all federally funded
efforts in Alzheimer's research, clinical care,
and institutional-, home-, and community-based
programs and their outcomes; and
(B) a summary of the Secretary's process for
identifying and updating what conditions
constitute Alzheimer's disease;
(2) an evaluation of all federally funded programs
based on program performance, mission, and purpose
related to Alzheimer's disease;
(3) recommendations for--
(A) priority actions based on the evaluation
conducted by the Secretary and the Advisory
Council to--
(i) reduce the financial impact of
Alzheimer's on--
(I) Medicare and other
federally funded programs; and
(II) families living with
Alzheimer's disease; and
(ii) improve health outcomes and
reduce disparities;
(B) implementation steps; and
(C) priority actions to improve the
prevention, diagnosis, treatment, care,
institutional-, home-, and community-based
programs of Alzheimer's disease for individuals
with Alzheimer's disease and their caregivers;
and
(4) an annually updated national plan.
(h) Sunset.--The Project shall expire on December 31, [2025]
2035.
[all]